Mangoceuticals

PlantX Life Inc. announces joint venture with LIV3 to launch SugarShield supplement, targeting the $5.24 billion weight loss management market. The supplement aims to boost energy, curb cravings, and simplify weight management without restrictive diets, leveraging PlantX's expertise in branding and digital platforms.

MangoRx refutes Eli Lilly's claims of improper copying of tirzepatide, the active ingredient in Lilly's weight-loss drugs Zepbound and Mounjaro, for its product Trim. The FDA allowed continued compounding of tirzepatide despite removing it from the shortage list, while Lilly sues over 20 entities for similar issues. MangoRx plans to defend itself vigorously.

Mangoceuticals, Inc. (NASDAQ: MGRX) announced a 1-for-15 reverse stock split effective October 16, 2024, aimed at regaining compliance with Nasdaq's minimum bid price requirement.

MangoRx launches TRIM, an oral Tirzepatide tablet for weight loss at $399/month, showing 15-25% weight reduction in clinical trials. The product offers a non-invasive alternative to injections, aligning with the growing demand for weight management solutions. MangoRx now offers Tirzepatide (TRIM) and Semaglutide (SLIM) options, positioning itself in the expanding GLP-1 market, projected to reach $157.5 billion by 2035.

MangoRx launches oral Semaglutide weight loss treatment 'Slim' to capitalize on growing GLP-1 market demand, priced at $299/month.

MangoRx launches 'Slim,' an oral Semaglutide weight loss treatment, aiming to capitalize on the growing demand for GLP-1 treatments and expand its market share in the weight loss category.